ATE157011T1 - Verabreichung von mitteln - Google Patents

Verabreichung von mitteln

Info

Publication number
ATE157011T1
ATE157011T1 AT91309102T AT91309102T ATE157011T1 AT E157011 T1 ATE157011 T1 AT E157011T1 AT 91309102 T AT91309102 T AT 91309102T AT 91309102 T AT91309102 T AT 91309102T AT E157011 T1 ATE157011 T1 AT E157011T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
antibody fragment
bind
binding
product
Prior art date
Application number
AT91309102T
Other languages
English (en)
Inventor
Thomas Stewart Beggs
Paul James Davis
Martine Elisa Verhoeyen
Original Assignee
Unilever Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Nv filed Critical Unilever Nv
Application granted granted Critical
Publication of ATE157011T1 publication Critical patent/ATE157011T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/94Involves covalent bonding to the substrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT91309102T 1990-10-05 1991-10-04 Verabreichung von mitteln ATE157011T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909021671A GB9021671D0 (en) 1990-10-05 1990-10-05 Delivery of agents

Publications (1)

Publication Number Publication Date
ATE157011T1 true ATE157011T1 (de) 1997-09-15

Family

ID=10683281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91309102T ATE157011T1 (de) 1990-10-05 1991-10-04 Verabreichung von mitteln

Country Status (11)

Country Link
US (1) US5490988A (de)
EP (1) EP0479600B1 (de)
JP (1) JPH04264036A (de)
AT (1) ATE157011T1 (de)
AU (1) AU653170B2 (de)
CA (1) CA2052713C (de)
DE (1) DE69127334T2 (de)
ES (1) ES2106057T3 (de)
GB (1) GB9021671D0 (de)
IN (1) IN174511B (de)
ZA (1) ZA917957B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2289679B (en) * 1993-01-15 1997-02-05 Imp Cancer Res Tech Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof
GB9300686D0 (en) * 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
US5486360A (en) * 1993-04-22 1996-01-23 St. Joseph Health Centre Method of treating tumour cells using catalase
EP0824019B1 (de) * 1996-08-13 2002-11-20 Quest International B.V. Hemmung oder Reduzierung des Mundgeruches
US6929936B1 (en) * 1997-07-18 2005-08-16 Danisco A/S Composition comprising an enzyme having galactose oxidase activity and use thereof
US5871714A (en) * 1997-10-16 1999-02-16 Pharmacal Biotechnologies, Inc. Compositions for controlling bacterial colonization
NL1009834C2 (nl) * 1998-08-10 2000-02-11 Stanislaus Laurens Johan Woute Antistoffen voor toepassing in de gerichte en tijdelijke behandeling van mens en dier.
AU3489700A (en) * 1999-02-12 2000-08-29 Pharmacal Biotechnologies, Llc Oral compositions and methods of production thereof
EP1212100B1 (de) * 1999-09-16 2005-04-06 Unilever Plc Abgabesystem für ein mittel gegen schuppen
US20020136732A1 (en) * 2000-04-23 2002-09-26 Houston L. L. Compositions comprising carriers and transportable complexes
US20030166160A1 (en) * 2001-09-06 2003-09-04 Hawley Stephen B. Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
US20030161809A1 (en) * 2000-10-02 2003-08-28 Houston L. L. Compositions and methods for the transport of biologically active agents across cellular barriers
US20040058865A1 (en) * 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
USD628808S1 (en) 2009-12-23 2010-12-14 Colgate-Palmolive Company Toothbrush
USD628389S1 (en) 2009-12-23 2010-12-07 Colgate-Palmolive Company Tissue cleaner
WO2012087966A2 (en) 2010-12-20 2012-06-28 E. I. Du Pont De Nemours And Company Targeted perhydrolases
BR112013015459B8 (pt) 2010-12-20 2018-06-12 Du Pont método, produto de cuidado oral e composição de geração de perácido

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
JPH0641424B2 (ja) * 1984-11-06 1994-06-01 ライオン株式会社 う蝕予防剤
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
DE3786000T3 (de) * 1986-08-18 1997-08-21 Dow Chemical Co Conjugate dichter Sterne.
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4943525A (en) * 1987-11-02 1990-07-24 Bioventures, Inc. Simultaneous immunoassay for the determination of antigens and antibodies
CA1341411C (en) * 1988-04-16 2002-12-17 Lutz Riechmann Method for producing fv fragments in eukaryotic cells
SE461570B (sv) * 1988-06-06 1990-03-05 Rama Bio Link Ab Farmaceutiskt preparat och konjugat av en baktericid och en antikropp
AU4402589A (en) * 1988-09-28 1990-04-18 Ideon Corporation Combination enzyme immunotherapeutics
ES2052027T5 (es) * 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
FR2643267A1 (fr) * 1989-02-23 1990-08-24 Centre Nat Rech Scient Compositions a proprietes cytolytiques specifiques vis-a-vis de cellules cibles appropriees et leurs applications
WO1991000108A1 (en) * 1989-06-30 1991-01-10 Brunswick Corporation Antibody-oxidase conjugates with non-systemic substrates
WO1991000112A1 (en) * 1989-06-30 1991-01-10 Brunswick Corporation Antibody-lactate oxidase conjugates
WO1991005856A1 (en) * 1989-10-13 1991-05-02 Loyola University Of Chicago Chimeric monoclonal antibodies generated by trans-splicing
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
AU642979B2 (en) * 1990-03-21 1993-11-04 Quest International B.V. Utilization and delivery of enzymes

Also Published As

Publication number Publication date
IN174511B (de) 1994-12-31
AU653170B2 (en) 1994-09-22
EP0479600A2 (de) 1992-04-08
CA2052713C (en) 1999-03-23
DE69127334T2 (de) 1998-01-15
EP0479600B1 (de) 1997-08-20
AU8555291A (en) 1992-04-09
DE69127334D1 (de) 1997-09-25
ZA917957B (en) 1993-04-05
US5490988A (en) 1996-02-13
EP0479600A3 (en) 1992-12-09
ES2106057T3 (es) 1997-11-01
JPH04264036A (ja) 1992-09-18
GB9021671D0 (en) 1990-11-21
CA2052713A1 (en) 1992-04-06

Similar Documents

Publication Publication Date Title
DE69127334D1 (de) Verabreichung von Mitteln
TR199802423T2 (xx) Konsantre antikor terkibi.
CY1110128T1 (el) Καταλυτικα μονοκλωνικα αντισωματα με δραστικοτητα πρωτεασης για την εκλεκτικη λυση του πρωτεϊνικου συστατικου των πλακων και συνονθυλευματων που σχετιζονται με παθολογικες καταστασεις
EP0662827A4 (de) Therapeutische und diagnostische verfahren und zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren.
BG95935A (bg) Метод и средство за приемане на дексмедетомидин директно през кожата
FR2710527B1 (fr) Nouvelles compositions cosmétiques et dermatologiques associant céramides et acide linoléique, leur préparation.
DE69512685D1 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
ATE123070T1 (de) Monoklonale antikörper gegen den rezeptor des epidermis-wachstumsfaktors und diese enthaltende therapeutische zubereitungen.
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
HUP9904023A2 (hu) Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
DE69434384D1 (de) Metalkomplexbildner
NO993866L (no) Legemiddel mot lymfatiske tumorer
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69806465D1 (de) Eine heteroethynylen-brücke enthaltende bi-aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammensetzungen
ATE159171T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
FI933506A7 (fi) Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaat teja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina
NO983220L (no) Sammensetninger og fremgangsmåter for å administrere Borrelia Burgdorferi-antigener
FR2636528B1 (fr) Composition capillaire pour la regeneration du derme humain ou animal

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties